🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,121 results for “ACE” Clear

  1. ACTISOUFRE, solution pour pulvérisation nasale/buccale en flacon pressurisé, Actisoufre Placebo

    Laboratoire HRA Pharma

    rhinosinusitis not requiring antibiotic therapy, rhinopharyngitis not requiring antibiotic therapy, Acute rhinitis not requiring antibiotic therapy

    phase 3 small molecule active

    1 trial

  2. AD04 (ondansetron)

    ADIAL PHARMACEUTICALS, INC.

    Alcohol Use Disorder

    phase 3 small molecule completed

    1 trial

  3. ADSTILADRIN

    Ferring Pharmaceuticals A/S

    Intermediate risk, non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial

  4. ADVATE 500 IU powder and solvent for solution for injection., VEYVONDI 1300 IU powder and solvent for solution for injection., ADVATE 1000 IU powder and solvent for solution for injection., VEYVONDI 650 IU powder and solvent for solution for injection.

    Takeda Pharmaceuticals International AG

    severe von Willebrand Disease

    phase 3 small molecule active

    1 trial

  5. AG-120/S95031 250mg film-coated tablet, Ivosidenib-matched Placebo Tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  6. ALPELISIB, FULVESTRANT, ALPELISIB, Placebo to BYL719 50 mg film-coated tablet Light pink Placebo to BYL719 200 mg film-coated tablet Light red

    Novartis Ophthalmics Europe

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  7. ALX1-11

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  8. ALX1-11 (drug)

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  9. ALXN1720 Placebo Product, Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  10. ALXN1850 placebo product, ALXN1850

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  11. ALXN1850, ALXN1850 placebo product

    Alexion Europe SAS

    hypophosphatasia

    phase 3 small molecule active

    1 trial

  12. ALXN2220 Placebo Product, Recombinant human anti-ATTR immunoglobulin G1 (IgG1) monoclonal antibody (mAb)

    Alexion Europe SAS

    Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

    phase 3 small molecule active

    1 trial

  13. AMG 133, AMG 133, AMG 133, AMG 133, Placebo for Maridebart cafraglutide

    Amgen Technology (Ireland) UC

    Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight

    phase 3 small molecule active

    1 trial

  14. AMG 133, Placebo for AMG 133 (maridebart cafraglutide)

    Amgen Technology (Ireland) UC

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  15. AMG 133, Placebo for AMG 133, AMG 133, AMG 133

    Amgen Technology (Ireland) UC

    "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"

    phase 3 small molecule active

    1 trial

  16. AMG 133, Placebo for Maridebart Cafraglutide

    Amgen Technology (Ireland) UC

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  17. AMG 479

    Takeda Pharmaceuticals International AG

    Adenocarcinoma of the Pancreas

    phase 3 small molecule completed

    1 trial

  18. AMG 706

    Takeda Pharmaceuticals International AG

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  19. AMPHORA

    Evofem Biosciences

    Contraception

    phase 3 small molecule completed

    1 trial

  20. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    5 trials

  21. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Progressive Supranuclear Palsy

    phase 3 small molecule completed

    1 trial

  22. ARALAST NP 60 mg/kg

    Takeda Pharmaceuticals International AG

    Chronic Obstructive Pulmonary Disease

    phase 3 mab terminated

    1 trial

  23. ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia (HTG)

    phase 3 small molecule active

    1 trial

  24. ARO-APOC3 PFS, ARO-APOC3, 0.9% Normal Saline for injection

    Arrowhead Pharmaceuticals Ireland Limited

    Familial Chylomicronemia Syndrome (FCS)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources